Biogen to apply for approval for antidepressant in 2022
After a short dialog with the authorities and its partner, Sage, Biogen is planning to start the application process for marketing authorization for its depression drug zuranolone in 2022. This is despite the fact that a recent study did not generate overwhelmingly convincing results.
by elizabeth mønsted johansen, translated by catherine brett
A press release from Biogen and Sage reports that applications for marketing authorization for zuranolone will start in 2022.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen Q3 results better than expected, updrades guidance
For subscribers
Biogen stumbles in crucial ALS study
For subscribers
